||WO||WO/2014/094844 - LOCALIZED DISINFECTION SYSTEM FOR LARGE WATER BODIES||26.06.2014||
||PCT/EP2012/076170||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN, Fernando Benjamin|
The present disclosure relates to a method for controlling the microbiological properties of a portion of water within a large body of water by treating such zone with chemical agents, according to the temperature of the water, its salinity, its dilution power and the diffusion of chemicals within the large water body.
||WO||WO/2013/124826 - OXAZOLIDIN- 2 -ONE COMPOUNDS AND USES THEREOF AS PI3KS INHIBITORS||29.08.2013||
||PCT/IB2013/051443||NOVARTIS AG||CARAVATTI, Giorgio|
The present invention relates to oxazolidin-2-one subsituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
||WO||WO/2013/111105 - IMIDAZOPYRROLIDINONE COMPOUNDS||01.08.2013||
||PCT/IB2013/050655||NOVARTIS AG||FURET, Pascal|
The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
||WO||WO/2013/107988 - METHOD FOR FORMULATING A VACCINE CONTAINING AT LEAST TWO ANTIGENS CAPABLE OF ADSORBING ONTO ALUMINIUM OXYHYDROXIDE||25.07.2013||
||PCT/FR2013/050106||SANOFI PASTEUR||BERTAUX, Landry|
The subject matter of the invention is a method for preparing a vaccine composition comprising at least aluminium oxyhydroxide (AlOOH), and at least the hepatitis B surface antigen and the Haemophilus influenzae type b antigen. According to the invention, the hepatitis B surface antigen is kept adsorbed on the AlOOH, whereas the Hib antigen is kept nonadsorbed. To this end: the hepatitis B surface antigen is adsorbed onto AlOOH in order to obtain an AlOOH/HBsAg complex, then - said AlOOH/HBsAg complex is mixed with the Hib antigen in the presence of cationic amino acids at a concentration of at least 100 mg/l, and of phosphate ions at a concentration of 35 to 45 mMol/l.
||WO||WO/2013/101261 - ISOTOPICALLY ALTERED OPTICAL FIBER||04.07.2013||
||PCT/US2012/023551||BELL, James, Dalton||BELL, James, Dalton|
An optical waveguide having a cladding layer formed of high-purity glass, or a cladding layer formed of high-purity isotope-proportion modified glass, and with a core of high-purity isotope-proportion-modified glass with the index of refraction of the core glass greater than the index of refraction, of the cladding glass, said high-purity isotope-proportion-modified core material having a Si-29-isotope proportion at most 4.447 % Si-29 (atom/atom) of all silicon atoms in said core, or at least 4.90% of Si-29 (atom/atom) atoms in said core, or having a Ge-73 isotope proportion of at most 7.2% Ge-73 (atom/atom) of all germanium atoms in said core, or at least 8.18% of Ge-73 (atom/atom) of Germanium atoms in said core region.
||WO||WO/2013/097980 - NIFURATEL SULFOXIDE FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS||04.07.2013||
||PCT/EP2012/072856||POLICHEM S.A.||GAGLIARDI, Stefania|
The present invention is directed to nifuratel sulfoxide, in particular, it is directed to the use of nifuratel sulfoxide, or a physiologically acceptable salt thereof, or a physiologically acceptable cocrystal thereof, to treat bacterial infections and, in particular, to treat infections caused by Atopobiwn and Gardnerelkt species. The invention is further directed to the use of nifuratel sulfoxide to treat bactenuria, urinary tract infections, infections of external genitalia in both sexes, as well as bacterial vaginosis, or mixed vaginal infections in women, when one or more species of the genera Atopobiwn and GardnereUa are among the causative pathogens of those infections.
||WO||WO/2013/092974 - QUINOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS||27.06.2013||
||PCT/EP2012/076590||H. LUNDBECK A/S||KEHLER, Jan|
The present invention provides quinoline derivatives of formula (I) that are PDE10A enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for PDE10 over other PDE subtypes. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
||WO||WO/2013/093401 - METHOD AND SYSTEM FOR SELECTIVE CHARGING BY RECIPIENTS OF IN-BOUND COMMUNICATIONS IN COMMUNICATION NETWORKS||27.06.2013||
||PCT/GB2012/000921||ARBOOSTER LIMITED||ABOU HAMZEH, Najib|
A method, in the field of communications services, for linking several electronic and information components (including communication network elements, servers, databases and software) to implement a service for, dynamically and selectively, imposing supplementary call charges on behalf of subscribers to the network; whether for self-employed, competent experts, other categories of content provider, or any individuals or organizations receiving communications. Such supplementary tariffs are levied on those calling telephone numbers dynamically and selectively dedicated for this purpose, providing called parties with a way to collect fees for the information they provide to calling parties. The method enables the operating party (a Value added service provider) in partnership with the mobile operator to collect these revenues on behalf of, and to share this revenue with, the called subscriber.
||WO||WO/2013/096679 - SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF||27.06.2013||
||PCT/US2012/071063||ALIOS BIOPHARMA, INC.||BEIGELMAN, Leonid|
Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.
||WO||WO/2013/091878 - PROCESS AND SYSTEM FOR CONVERSION OF CARBON DIOXIDE TO CARBON MONOXIDE||27.06.2013||
||PCT/EP2012/005309||CCP TECHNOLOGY GMBH||KÜHL, Olaf|
A process and a device for converting carbon dioxide CO2 to carbon monoxide CO, using hydrocarbons are described. In further details, processes and devices are described for generating synthesis gases and processes and devices are described for converting synthesis gases to synthetic functionalized and/or non-functionalized hydrocarbons, using CO2 and hydrocarbons. By means of the processes and the devices, carbon dioxide emitted from industrial process can be converted and the amount of carbon dioxide released into the atmosphere can be decreased.